Proposed Issue and Placing | 26-Oct-2023 | 16:30 | RNS |
Faron Announces Positive BEXMAB Study Update | 11-Oct-2023 | 07:00 | RNS |
Board Changes | 22-Sep-2023 | 16:00 | RNS |
Results of EGM | 22-Sep-2023 | 11:00 | RNS |
Faron Appoints Interim Chief Medical Officer | 21-Sep-2023 | 07:00 | RNS |
Change in the Board of Directors | 08-Sep-2023 | 07:00 | RNS |
Notice of EGM | 01-Sep-2023 | 10:00 | RNS |
Exercise of options | 31-Aug-2023 | 14:00 | RNS |
Faron 2023 Half-Year Financial Results | 29-Aug-2023 | 07:01 | RNS |
FDA Orphan Drug Designation for Bexmarilimab | 29-Aug-2023 | 07:00 | RNS |
Notice of Half-Year Financial Results | 04-Aug-2023 | 07:00 | RNS |
Grant of Options | 25-Jul-2023 | 07:00 | RNS |
BEXMAB study update | 19-Jul-2023 | 07:00 | RNS |
Holding(s) in Company | 30-Jun-2023 | 16:52 | RNS |
Announcement of Placing | 29-Jun-2023 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 150.00p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 350.00 |
52 Week Low | 117.50 |
Volume | 8,165 |
Shares Issued | 72.01m |
Market Cap | £108.01m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 1 |
Neutral | 0 |
Sell | 1 |
Strong Sell | 1 |
Total | 3 |
No dividends found |
Time | Volume / Share Price |
13:53 | 1,239 @ 153.00p |
10:51 | 20 @ 147.20p |
10:44 | 3,645 @ 148.00p |
08:18 | 3,261 @ 153.00p |
CEO | Juho Jalkanen |
Chair | Tuomo Pätsi |
You are here: research